Abstract
EudraCT n°: 2018-003832-57 DOLAF-An international multicenter phase II trial of Durvalumab (MEDI4736) plus OLAparib plus Fulvestrant in metastatic or locally advanced ER-positive, HER2-negative breast cancer patients selected using criteria that predict sensitivity to olaparib.

This publication has 56 references indexed in Scilit: